Skip to main content
An irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been approved for first-line treatment of non-small cell lung cancer (NSCLC) with certain EGFR mutations.

Pharmacology Update: Afatinib Tablets (Gilotrif™)